Vimarsana
Biggest News Aggregation in the World

Session Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Session Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Session Details Today - Breaking & Trending Today

Multiple New Analyses Reinforce the Role of BAVENCIO avelumab FirstLine Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Vimarsana News

Multiple New Analyses Reinforce the Role of BAVENCIO avelumab FirstLine Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published: January 23, 2024

Merck a leading science and technology company today announced new realworld data that continue to reinforce the JAVELIN Bladder regimen of firstline platinumbased chemotherapy followed by BAVENCIO avelumab maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma UC who do not progress on firstline chemotherapy.

Source: businesswireindia.com
Related Topics:
United StatesCzech RepublicSan FranciscoPhilippe BarthAmerican Society Of Clinical OncologyAmerican Cancer SocietyClinical OncologyGenitourinary Cancers SymposiumInstitut De CancStrasbourg EuropeWorld StudyReal World StudyReported OutcomesNational Comprehensive CancerFunctional AssessmentCancer Therapy Bladder SymptomSenior Vice PresidentMedical Unit OncologySession DetailsProduct CharacteristicsCancer JournalAccessed FebruaryUnited Kingdom BasedMedia ContactMerck Bavencio Avelumab Metastatic Urothelial Carcinoma Genitourinary Cancers Symposium Chemotherapy Javelin Bladder Adc Therapy Science Technology Overall Survival Antibody Drug Conjugate American Society Of Clinical Oncology Philippe Barthelemy Avenance Study Enfortumab Vedotin 100 Bmi Tamas Suto Pharmacokinetics Immunogenicity Cancer Axitinib Merkel Cell
Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breast™ qPCR Blood Test in Early-Stage Breast Cancer - Vimarsana News

Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breast™ qPCR Blood Test in Early-Stage Breast Cancer

Published: December 1, 2023

/PRNewswire/ -- Mammogen, a pioneering leader in women's health and a subsidiary of early detection parent company, IVBH, is set to present groundbreaking...

Source: prnewswire.com
Related Topics:
United StatesSan AntonioElizabeth CormierHenryb Gonzalez Convention CenterAntonio Breast Cancer SymposiumSession DetailsPoster SessionConvention Center
Merck: New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma - Vimarsana News

Merck: New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Published: February 14, 2023

Not intended for UK-based media Long-term follow-up of the Phase III JAVELIN Bladder 100 study demonstrated median overall survival from start of chemotherapy of 29.7 months among patients receiving

Source: finanznachrichten.de
Related Topics:
United StatesSrikala SridharAmerican Society Of Clinical OncologyMerck PressEuropean CommissionDrug AdministrationPrincess Margaret Cancer CentreMerck KgaMerck KgaaAmerican Cancer SocietyUnited Kingdom BasedClinical OncologyGenitourinary Cancers SymposiumSenior Vice President HeadMedical Unit OncologySession DetailsProstate CancerUrothelial CarcinomaRenal Cell CancerTesticular CancersUnited KingdomProduct CharacteristicsMerck Press ReleasesCancer JournalAccessed February
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma - Vimarsana News

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Published: February 14, 2023

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.

Source: businesswireindia.com
Related Topics:
United StatesSrikala SridharAmerican Society Of Clinical OncologyMerck PressEuropean CommissionDrug AdministrationPrincess Margaret Cancer CentreMerck KgaMerck KgaaAmerican Cancer SocietyUnited Kingdom BasedClinical OncologyGenitourinary Cancers SymposiumSenior Vice PresidentMedical Unit OncologySession DetailsProstate CancerRenal Cell CancerUnited KingdomProduct CharacteristicsMerck Press ReleasesCancer JournalAccessed FebruaryMedia ContactMerck Kgaa
Radhika Bhachu, Ndovu co-founder among 3 Kenyan female founders selected to join The Future is Female Mentorship Program - Vimarsana News

Radhika Bhachu, Ndovu co-founder among 3 Kenyan female founders selected to join The Future is Female Mentorship Program

Published: September 9, 2022

Three Kenyan female founders are among the Twenty-five African female-founded tech startups selected for the third edition of The Future is Female Mentorship Program. They are Wambui Karingithi (Chiza Health) ,Radhika Bhachu (Ndovu) and Linet Kinyua (Pensoft System Limited).

Source: hapakenya.com
Related Topics:
David IdaguRadhika Bhachu NdovuClaudine MooreWambui Karingithi Chiza HealthAfrica Communications WeekInternational Public RelationsMentorship ProgramLinet Kinyua Pensoft SystemTwenty Five AfricanFemale MentorshipWambui KaringithiChiza HealthRadhika BhachuLinet KinyuaPensoft System LimitedFemale Mentorship ProgramNew York HeadquarteredSession DetailsTope Adubi